CORCEPT THERAPEUTICS INC Earnings Per Share (Basic)
CORCEPT THERAPEUTICS INC (CORT) reported Earnings Per Share (Basic) of $0.40 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC earnings per share, basic for the quarter ending 2026-06-30 was $0.40, a 21.21% increase year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, basic for the quarter ending 2026-03-31 was -$0.30, a 257.89% decline year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, basic for the quarter ending 2025-12-31 was $0.23, a 21.37% decline year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, basic for the quarter ending 2025-09-30 was $0.19, a 57.78% decline year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, basic for fiscal 2025 was $0.95, a 29.63% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC earnings per share, basic for fiscal 2024 was $1.35, a 32.35% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC earnings per share, basic for fiscal 2023 was $1.02, a 7.37% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC earnings per share, basic for fiscal 2022 was $0.95, a 2.06% decline from fiscal 2021.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.40 10-Q · filed 2026-07-29 | $0.11 10-Q · filed 2026-07-29 | $0.33 derived: net income ÷ weighted average shares · filed 2026-07-29 | $0.52 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2026-03-31 | -$0.30 10-Q · filed 2026-04-30 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.12 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.45 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2025-12-31 | $0.23 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.42 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.75 derived: net income ÷ weighted average shares · filed 2026-07-29 | $0.95 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.19 10-Q · filed 2025-11-04 | $0.52 derived: net income ÷ weighted average shares · filed 2026-07-29 | $0.71 10-Q · filed 2025-11-04 | $1.01 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2025-06-30 | $0.33 10-Q · filed 2026-07-29 | $0.53 10-Q · filed 2026-07-29 | $0.82 derived: net income ÷ weighted average shares · filed 2026-07-29 | $1.27 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2025-03-31 | $0.19 10-Q · filed 2026-04-30 | $0.49 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.94 derived: net income ÷ weighted average shares · filed 2026-04-30 | $1.28 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-12-31 | $0.29 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.74 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.09 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.35 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.45 10-Q · filed 2025-11-04 | $0.79 derived: net income ÷ weighted average shares · filed 2025-11-04 | $1.06 10-Q · filed 2025-11-04 | $1.36 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2024-06-30 | $0.34 10-Q · filed 2025-07-31 | $0.61 10-Q · filed 2025-07-31 | $0.91 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.22 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2024-03-31 | $0.27 10-Q · filed 2025-05-05 | $0.57 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.88 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.15 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2023-12-31 | $0.30 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.61 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.88 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.02 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.31 10-Q · filed 2024-10-30 | $0.57 derived: net income ÷ weighted average shares · filed 2024-10-30 | $0.72 10-Q · filed 2024-10-30 | $0.87 derived: net income ÷ weighted average shares · filed 2025-02-26 |
| 2023-06-30 | $0.27 10-Q · filed 2024-07-29 | $0.41 10-Q · filed 2024-07-29 | $0.56 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.89 derived: net income ÷ weighted average shares · filed 2025-02-26 |
| 2023-03-31 | $0.15 10-Q · filed 2024-05-01 | $0.30 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.62 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.88 derived: net income ÷ weighted average shares · filed 2025-02-26 |
| 2022-12-31 | $0.15 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.48 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.73 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.95 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.32 10-Q · filed 2023-11-01 | $0.58 derived: net income ÷ weighted average shares · filed 2023-11-01 | $0.80 10-Q · filed 2023-11-01 | $1.08 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2022-06-30 | $0.26 10-Q · filed 2023-08-02 | $0.47 10-Q · filed 2023-08-02 | $0.76 derived: net income ÷ weighted average shares · filed 2024-02-15 | $1.02 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2022-03-31 | $0.22 10-Q · filed 2023-05-03 | $0.50 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.76 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.99 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2021-12-31 | $0.28 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.54 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.77 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.97 10-K · filed 2024-02-15 |
| 2021-09-30 | $0.26 10-Q · filed 2022-11-03 | $0.49 derived: net income ÷ weighted average shares · filed 2022-11-03 | $0.69 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.23 10-Q · filed 2022-08-04 | $0.43 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.20 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.22 10-K · filed 2021-02-23 | $0.92 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.19 10-Q · filed 2021-11-03 | $0.70 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $0.25 10-Q · filed 2021-07-29 | $0.51 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $0.26 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.26 10-K · filed 2021-02-23 | $0.82 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $0.23 10-K · filed 2021-02-23 | $0.57 10-Q · filed 2020-11-03 | ||
| 2019-06-30 | $0.18 10-K · filed 2021-02-23 | $0.34 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $0.16 10-K · filed 2021-02-23 | |||
| 2018-12-31 | $0.19 10-K · filed 2020-02-24 | $0.65 10-K · filed 2021-02-23 | ||
| 2018-09-30 | $0.15 10-K · filed 2020-02-24 | $0.46 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $0.16 10-K · filed 2020-02-24 | $0.31 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $0.15 10-K · filed 2020-02-24 | |||
| 2017-12-31 | $0.86 10-K · filed 2019-02-26 | $1.14 10-K · filed 2020-02-24 | ||
| 2017-09-30 | $0.12 10-K · filed 2019-02-26 | $0.27 10-Q · filed 2018-11-02 | ||
| 2017-06-30 | $0.11 10-K · filed 2019-02-26 | $0.15 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $0.04 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $0.07 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $0.02 10-Q · filed 2017-11-03 | $0.03 10-Q · filed 2017-11-03 | ||
| 2016-06-30 | $0.01 10-Q · filed 2017-08-02 | $0.01 10-Q · filed 2017-08-02 | ||
| 2015-12-31 | -$0.06 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |